Department of Anesthesiology, University of British Columbia, Vancouver, BC, Canada.
Research Department, Salem Anesthesia Pain Clinic Surrey, Vancouver, BC, Canada.
J Clin Sleep Med. 2022 Jun 1;18(6):1565-1571. doi: 10.5664/jcsm.9930.
Chronic pain is associated with insomnia. The objective of this clinical study was to compare the efficacy and safety of different prescribed doses of zopiclone and clonidine for the management of insomnia in patients with chronic pain.
This prospective observational crossover study included 160 consenting adult patients receiving pain management treatment. For insomnia treatment, each patient ingested different prescribed doses of zopiclone or clonidine on alternate nights. Each patient used a special validated sleep diary to collect data including pain score, sleep scores, sleep duration, sleep medication dose, and adverse effects. Each patient completed the diary for 3 continuous weeks. Pain was measured using a numeric pain rating scale. Sleep score was measured using the Likert Sleep Scale. A change in the pain or sleep scores by 2 points was considered significant. Of the 160 study participants, 150 (93.8%) completed the study successfully, and their data were analyzed with IBM SPSS Statistics 25 (IBM Corporation, Armonk, NY) using Student's test, analysis of variance, Pearson chi-square test, and regression analysis. A value < .05 was considered significant.
Pain score was lower with clonidine than zopiclone ( = .025). Time to fall asleep was shorter with clonidine than zopiclone ( = .001). Feeling rested on waking in the morning was better with clonidine than zopiclone ( = .015). Overall sleep quality was better with clonidine than zopiclone ( = .015). Total Likert sleep score was better with clonidine than zopiclone ( = .005). Total sleep duration was better with clonidine than zopiclone ( = .013). Adverse effects were commoner with zopiclone, including collapse, fall, confusion, amnesia, mood disorder, hallucination, nightmare, nocturnal restlessness, locomotor dysfunction, nausea and headache. A minor adverse effect of dry mouth was commoner with clonidine.
Clonidine is significantly better than zopiclone with respect to sleep quality, analgesia, tolerability profile, and patient safety. Further studies comparing clonidine with other insomnia medications will be beneficial.
Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, et al. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. . 2022;18(6):1565-1571.
慢性疼痛与失眠有关。本临床研究的目的是比较不同处方剂量佐匹克隆和可乐定治疗慢性疼痛患者失眠的疗效和安全性。
这是一项前瞻性观察性交叉研究,纳入了 160 名接受疼痛管理治疗的同意成人患者。对于失眠治疗,每位患者在不同的夜晚服用不同处方剂量的佐匹克隆或可乐定。每位患者使用特殊的经过验证的睡眠日记收集数据,包括疼痛评分、睡眠评分、睡眠时间、睡眠药物剂量和不良反应。每位患者连续 3 周完成日记。疼痛使用数字疼痛评分量表测量。睡眠评分使用李克特睡眠量表测量。疼痛或睡眠评分变化 2 分被认为具有显著意义。在 160 名研究参与者中,有 150 名(93.8%)成功完成了研究,他们的数据使用 IBM SPSS Statistics 25(IBM 公司,纽约州阿蒙克)进行分析,使用学生 t 检验、方差分析、皮尔逊卡方检验和回归分析。 值<0.05 被认为具有显著意义。
与佐匹克隆相比,可乐定的疼痛评分较低(=0.025)。与佐匹克隆相比,可乐定的入睡时间更短(=0.001)。与佐匹克隆相比,可乐定醒来时感觉更有精神(=0.015)。与佐匹克隆相比,可乐定的整体睡眠质量更好(=0.015)。总李克特睡眠评分可乐定优于佐匹克隆(=0.005)。可乐定的总睡眠时间优于佐匹克隆(=0.013)。佐匹克隆更常见不良反应,包括晕倒、跌倒、意识模糊、健忘、情绪障碍、幻觉、噩梦、夜间不安、运动功能障碍、恶心和头痛。可乐定更常见轻微的口干不良反应。
可乐定在睡眠质量、镇痛、耐受性和患者安全性方面明显优于佐匹克隆。比较可乐定与其他失眠药物的进一步研究将是有益的。
Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, et al. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients.. 2022;18(6):1565-1571.